

PRESS RELEASE

Change in number of shares and votes in Camurus

Lund, Sweden — 31 May 2023 — During May 2023, 35,450 subscription warrants in Camurus' subscription warrant series TO2020/2023 have been exercised and as a consequence the number of shares and votes has increased by 35,450.

Prior to the exercise, the total number of shares in Camurus amounted to 55,423,043, corresponding to 55,423,043 votes. As of 31 May 2023, the total number of shares in Camurus amounts to 55,458,493 corresponding to 55,458,493 votes.

For more information

Fredrik Tiberg, President & CEO

Tel. +46 (0)46 286 46 92

fredrik.tiberg@camurus.com

Fredrik Joabsson, Chief Business Development Officer

Tel. +46 (0)70 776 17 37

ir@camurus.com

About Camurus

Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus' clinical pipeline includes products for the treatment of dependence, pain, cancer, and endocrine disorders, developed in-house and in collaboration with international pharmaceutical companies. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.

The information is such that Camurus AB is obliged to make public pursuant to Chapter 4, Section 9 of the Swedish Financial Instruments Trading Act. The information was submitted for publication on 31 May 2023 at 7.00 am CET.